IMPORTANCE: Mental stress can induce myocardial ischemia and also has been implicated in triggering cardiac events. However, pharmacological interventions aimed at reducing mental stress-induced myocardial ischemia (MSIMI) have not been well studied. OBJECTIVE: To examine the effects of 6 weeks of escitalopram treatment vs placebo on MSIMI and other psychological stress-related biophysiological and emotional parameters. DESIGN, SETTING, AND PARTICIPANTS: The REMIT (Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment) study, a randomized, double-blind, placebo-controlled trial of patients with clinically stable coronary heart disease and laboratory-diagnosed MSIMI. Enrollment occurred from July 24, 2007, through August 24, 2011, at a tertiary medical center. INTERVENTIONS:Eligible participants were randomized 1:1 to receive escitalopram (dose began at 5 mg/d, with titration to 20 mg/d in 3 weeks) or placebo over 6 weeks. MAIN OUTCOMES AND MEASURES: Occurrence of MSIMI, defined as development or worsening of regional wall motion abnormality; left ventricular ejection fraction reduction of 8% or more; and/or horizontal or down-sloping ST-segment depression of 1 mm or more in 2 or more leads, lasting for 3 or more consecutive beats, during 1 or more of 3 mental stressor tasks. RESULTS: Of 127 participants randomized to receiveescitalopram (n = 64) or placebo (n = 63), 112 (88.2%) completed end point assessments (n = 56 in each group). At the end of 6 weeks, more patients taking escitalopram (34.2% [95% CI, 25.4%-43.0%]) had absence of MSIMI during the 3 mental stressor tasks compared with patients taking placebo (17.5% [95% CI, 10.4%-24.5%]), based on the unadjusted multiple imputation model for intention-to-treat analysis. A significant difference favoring escitalopram was observed (odds ratio, 2.62 [95% CI, 1.06-6.44]). Rates of exercise-induced ischemia were slightly lower at 6 weeks in the escitalopram group (45.8% [95% CI, 36.6%-55.0%]) than in patients receiving placebo (52.5% [95% CI, 43.3%-61.8%]), but this difference was not statistically significant (adjusted odds ratio; 1.24 [95% CI, 0.60-2.58]; P = .56). CONCLUSIONS AND RELEVANCE: Among patients with stable coronary heart disease and baseline MSIMI, 6 weeks of escitalopram, compared withplacebo, resulted in a lower rate of MSIMI. There was no statistically significant difference in exercise-induced ischemia. Replication of these results in multicenter settings and investigations of other medications for reducing MSIMI are needed. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00574847.
RCT Entities:
IMPORTANCE: Mental stress can induce myocardial ischemia and also has been implicated in triggering cardiac events. However, pharmacological interventions aimed at reducing mental stress-induced myocardial ischemia (MSIMI) have not been well studied. OBJECTIVE: To examine the effects of 6 weeks of escitalopram treatment vs placebo on MSIMI and other psychological stress-related biophysiological and emotional parameters. DESIGN, SETTING, AND PARTICIPANTS: The REMIT (Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment) study, a randomized, double-blind, placebo-controlled trial of patients with clinically stable coronary heart disease and laboratory-diagnosed MSIMI. Enrollment occurred from July 24, 2007, through August 24, 2011, at a tertiary medical center. INTERVENTIONS: Eligible participants were randomized 1:1 to receive escitalopram (dose began at 5 mg/d, with titration to 20 mg/d in 3 weeks) or placebo over 6 weeks. MAIN OUTCOMES AND MEASURES: Occurrence of MSIMI, defined as development or worsening of regional wall motion abnormality; left ventricular ejection fraction reduction of 8% or more; and/or horizontal or down-sloping ST-segment depression of 1 mm or more in 2 or more leads, lasting for 3 or more consecutive beats, during 1 or more of 3 mental stressor tasks. RESULTS: Of 127 participants randomized to receive escitalopram (n = 64) or placebo (n = 63), 112 (88.2%) completed end point assessments (n = 56 in each group). At the end of 6 weeks, more patients taking escitalopram (34.2% [95% CI, 25.4%-43.0%]) had absence of MSIMI during the 3 mental stressor tasks compared with patients taking placebo (17.5% [95% CI, 10.4%-24.5%]), based on the unadjusted multiple imputation model for intention-to-treat analysis. A significant difference favoring escitalopram was observed (odds ratio, 2.62 [95% CI, 1.06-6.44]). Rates of exercise-induced ischemia were slightly lower at 6 weeks in the escitalopram group (45.8% [95% CI, 36.6%-55.0%]) than in patients receiving placebo (52.5% [95% CI, 43.3%-61.8%]), but this difference was not statistically significant (adjusted odds ratio; 1.24 [95% CI, 0.60-2.58]; P = .56). CONCLUSIONS AND RELEVANCE: Among patients with stable coronary heart disease and baseline MSIMI, 6 weeks of escitalopram, compared with placebo, resulted in a lower rate of MSIMI. There was no statistically significant difference in exercise-induced ischemia. Replication of these results in multicenter settings and investigations of other medications for reducing MSIMI are needed. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00574847.
Authors: Thomas W Kamarck; Matthew F Muldoon; Stephen B Manuck; Roger F Haskett; Jeewon Cheong; Janine D Flory; Elizabeth Vella Journal: Psychoneuroendocrinology Date: 2011-02-08 Impact factor: 4.905
Authors: Alexander H Glassman; Christopher M O'Connor; Robert M Califf; Karl Swedberg; Peter Schwartz; J Thomas Bigger; K Ranga Rama Krishnan; Louis T van Zyl; J Robert Swenson; Mitchell S Finkel; Charles Landau; Peter A Shapiro; Carl J Pepine; Jack Mardekian; Wilma M Harrison; David Barton; Michael Mclvor Journal: JAMA Date: 2002-08-14 Impact factor: 56.272
Authors: T C Andrews; J D Parker; S Jacobs; R Friedman; N Cummings; G MacCallum; F Mannting; G H Tofler; W Carlson; J E Muller; P H Stone Journal: J Am Coll Cardiol Date: 1998-11-15 Impact factor: 24.094
Authors: W Jiang; M Babyak; D S Krantz; R A Waugh; R E Coleman; M M Hanson; D J Frid; S McNulty; J J Morris; C M O'Connor; J A Blumenthal Journal: JAMA Date: 1996-06-05 Impact factor: 56.272
Authors: Jingkai Wei; Cherie Rooks; Ronnie Ramadan; Amit J Shah; J Douglas Bremner; Arshed A Quyyumi; Michael Kutner; Viola Vaccarino Journal: Am J Cardiol Date: 2014-05-01 Impact factor: 2.778
Authors: Redford B Williams; George D Bishop; Brett C Haberstick; Andrew Smolen; Beverly H Brummett; Ilene C Siegler; Michael A Babyak; Xiaodong Zhang; E Shyong Tai; Jeannette Jen-Mai Lee; Maudrene Tan; Yik Ying Teo; Shiwei Cai; Edmund Chan; Carolyn Tucker Halpern; Eric A Whitsel; Shawn Bauldry; Kathleen Mullan Harris Journal: Am Heart J Date: 2016-12-29 Impact factor: 4.749
Authors: Julia L Sun; Stephen H Boyle; Zainab Samad; Michael A Babyak; Jennifer L Wilson; Cynthia Kuhn; Richard C Becker; Thomas L Ortel; Redford B Williams; Joseph G Rogers; Christopher M O'Connor; Eric J Velazquez; Wei Jiang Journal: Eur J Prev Cardiol Date: 2017-01-09 Impact factor: 7.804
Authors: James A Blumenthal; Bryan J Feger; Patrick J Smith; Lana L Watkins; Wei Jiang; Jonathan Davidson; Benson M Hoffman; Megan Ashworth; Stephanie K Mabe; Michael A Babyak; William E Kraus; Alan Hinderliter; Andrew Sherwood Journal: Am Heart J Date: 2016-03-12 Impact factor: 4.749